Braveheart’s board is made up of two executive directors and two non-executive directors.
We expect all our directors to devote as much time as is required to carry out the roles and responsibilities they have each agreed to take on. This generally means that Vivian Hallam and Trevor Brown are full time and Sue Hagan and Qu Li are part time.
You can read more about each of our directors below
Executive and non-executive directors are re-elected at least once every three years. You can inspect the letters of appointment for all Braveheart’s directors at our registered office during normal business hours.
The board meets at least eight times a year to formulate, review and approve the group’s strategy, budgets, performance, major capital expenditure and corporate actions. Meetings are open and constructive and every director participates fully.
The board also has an audit committee and a remuneration committee. As appointments to the board are made by the board as a whole there is no need for a nominations committee.
Trevor joined the Board of Braveheart as a non-executive director on 1 April 2014 and was appointed CEO on 24 August 2015.
He has worked as a director in a number of businesses over many years, the most recent being Feedback plc, Management Resource Solutions plc and Advanced Oncotherapy plc. He is currently CEO of IQ-AI Limited and a non-executive director of Chamberlin plc.
Viv has been Executive Director and COO for Braveheart since 2017. He manages the operational functions and investment portfolio. He is also a non-executive director for several of Braveheart’s portfolio of companies. Viv is a member of the Audit Committee.
Viv joined Braveheart in 2009, when it acquired the consulting and fund management company Inkopo. He had previously worked in product development for the automotive engineering sector and international sales management for a Swiss group. He is a Chartered Engineer and has an MBA from Aston University.
Sue joined the Braveheart Board in May 2021 as a non-executive director and is a member of both the Remuneration Committee and the Audit Committee.
Sue has over 20 years of experience in the pharmaceutical and medical device industries, including big pharma and start-up companies, covering project management, early-phase research and development, lab management, regulatory and clinical studies. She is a registered pharmacist with a PhD in drug delivery.
Qu joined the Braveheart Board on 16 June 2021 and is a member of the Remuneration and Audit and Committees.
Qu is an experienced entrepreneur, investor and businesswoman with over 30 years of experience in corporate mergers and acquisitions, development and restructuring; and financing and investments. She is currently a non-executive director of IQ-AI Limited and CEO of Morris Commercial Limited.